Magle Group secures SEK 25M emergency loan from existing bondholders amid restructuring
What's the deal? Swedish life sciences company Magle Group has entered into a loan facility agreement of up to SEK 60M with a group of its existing bondholders. The initial drawdown is SEK 25M, with up to SEK 35M available in additional tranches. The loan is designed to keep the company running while it works through an ongoing restructuring process.
The facility carries interest at 3-month STIBOR plus 5.25% per annum, payable quarterly, and matures one year from signing. As security, Magle Group and its subsidiary Magle ChemoswedDealroom has a profile for this one. Try Dealroom → AB have granted first-ranking security over rights under certain royalty agreements.
In exchange for the financing, Magle Group will issue "bonus bonds" equal to 5% of the utilised loan amount — SEK 1.25M on the initial drawdown — which lenders may later convert into common shares through a directed share issue.
Why now? Magle Group is under the clock. In April, bondholders approved a waiver of maintenance tests on its SEK 350M senior secured bonds, but only on the condition that the company raises at least SEK 100M in net proceeds by June 30, 2026. The company needs near-term liquidity to bridge operations while it pursues that target and executes its broader restructuring plan.
What could go wrong? The facility still requires further bondholder approval through a written procedure to permit security-sharing arrangements and the issuance of bonus bonds. If bondholders block those amendments, the deal's structure could unravel.
There is also the question of dilution. Converting bonus bonds into equity would dilute existing shareholders, and the conversion price has yet to be agreed with lenders. Meanwhile, the company must still raise the SEK 100M required under its earlier bondholder agreement — a tall order for a firm already in distress.
The loan itself is relatively short-dated. If Magle Group cannot stabilise its finances within a year, it faces a fresh repayment cliff.
The signal: Magle Group's rescue financing underscores a broader pattern across distressed Nordic mid-caps, where existing bondholders increasingly prefer to extend lifelines — complete with equity sweeteners — rather than force an insolvency that could crystallise steeper losses. The bonus-bond conversion mechanism effectively prices the lenders' risk appetite: they want downside protection today and upside optionality if the restructuring succeeds, a playbook that shifts meaningful dilution risk onto existing shareholders.
Read more: Nasdaq
